Activation of Rb and decline in androgen receptor protein precede retinoic acid-induced apoptosis in androgen-dependent LNCaP cells and their and their androgen-independent derivative

Journal of Cellular Physiology

Volumn 179, Issue 3, 1999, Pages 336-346

  Gao, Min ^a   Ossowski, Liliana ^a   Ferrari, Anna C ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; CYTOKERATIN; DOXORUBICIN; PACLITAXEL; PROSTATE SPECIFIC ANTIGEN; PROTEIN BCL 2; PROTEIN P21; RECEPTOR PROTEIN; RETINOBLASTOMA PROTEIN; RETINOIC ACID;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER RECURRENCE; CANCER REGRESSION; DRUG RESISTANCE; HORMONE INHIBITION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROSTATE CANCER;

ANTIGENS, SURFACE; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BLOTTING, WESTERN; CARBOXYPEPTIDASES; CELL DIFFERENTIATION; CELL DIVISION; DIHYDROTESTOSTERONE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; DOXORUBICIN; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUTAMATE CARBOXYPEPTIDASE II; GROWTH INHIBITORS; HUMANS; KERATINS; MALE; PACLITAXEL; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; RETINOBLASTOMA PROTEIN; TRETINOIN; TUMOR CELLS, CULTURED;

EID: 0032960413     PISSN: 00219541     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-4652(199906)179:3<336::AID-JCP11>3.0.CO;2-Q     Document Type: Article

References (43)

1. Bookstein R, Shew J-Y, Chen P-L, Scully P, Lee W-H. 1990. Suppression of tumorigenicity of human prostate carcinoma cells by replacing a mutated RB gene. Science 247:712-715.
2. Bruchovsky N, Rennie PS, Coldman AJ, Goldenberg SL, To M, Lawson D. 1990. Effects of androgen withdrawal on the stem cell composition of the shionogi carcinoma. Cancer Res 50:2275-2282.
3. Clarke CC, Graham J, Roman SD, Sutherland RL. 1991. Direct transcriptional regulation of the progesterone receptor by retinoic acid diminishes progestin responsiveness in the breast cancer cell line T-47D. J Biol Chem 266:18969-18975.
4. Culig Z, Hobisch A, Cronauer MV, Hittmair A, Radmayr C, Bartsch G, Klocker H. 1995. Activation of the androgen receptor by polypeptide growth factors and cellular regulators. Worl J Urol 13:285-289.
5. Culig Z, Hobisch A, Cronauer MV, Cato ACB, Hittmair A, Radmayr C, Eberie J, Bartsch G, Klocker H. 1993. Mutant androgen receptor detected in an advanced-stage prostatic carcinoma is activated by adrenal androgens and progesterone. Mol Endocrinol 7:1541-1550.
6. Day ML, Foster R, Day KC, Zhao X, Humphrey P, Swanson P, Postigo AA, Zhang SH, Dean DC. 1996. Cell anchorage regulates apoptosis through the retinoblastoma tumor suppressor/E2F pathway. J Biol Chem 272:8125-8128.
7. Delia D, Aiello A, Formelli F, Fontanella E, Costa A, Miyashita T, Reed J, Perotti M. 1995. Regulation of apoptosis by the Retinoid N-(4-Hydroxyphenyl) Retinamide and effect of deregulated bcl-2. Blood 85:359-367.
8. 1 arrest and apoptosis. Cancer Res 54:1169-1174.
9. Ferrari AC, Waxman S. 1994. In: Pinedo HM, Longo DL, Chabner BA, editors. Cancer chemotherapy and biological response modifiers, vol 15. Amsterdam: Elsevier Science, p 337-366.
10. Fong C-J, Sutkowski DM, Braun EJ, Bauer KD, Sherwood ER, Lee C, Kozlowski JM. 1993. Effect of retinoic acid on the proliferation and secretory activity of androgen-responsive prostatic carcinoma cells. J Urol 149:1190-1194.
11. Gaddipati JP, McLeod DG, Heidenberg HB, Sesterhenn IA, Finger MJ, Moul JW, Srivastava S. 1994. Frequent detection of codon 877 mutation in the androgen receptor gene in advanced prostate cancers. Cancer Res 54:2861-2864.
12. Gong Y, Blok LJ, Perry JE, Lindzey JK, Tindall DJ. 1995. Calcium regulation of androgen receptor expression in the human prostate cancer cell line LNCaP. Endocrinology 135:2172-2178.
13. Haldar S, Chintapalli J, Croce CM. 1996. Taxol induces bcl-2 phosphorylation and death of prostate cancer cells. Cancer Res 56:1253-1255.
14. Halgunset J, Sunde A, Lundmo PI. 1987. Retinoic acid (RA): an inhibitor of 5α-reductase in human prostatic cancer cells. J Steroid Biochem 28:731-736.
15. Hall RE, Tilley WD, McPhaul MJ, Sutherland RL. 1992. Regulation of androgen receptor gene expression by steroids and retinoic acid in human breast-cancer cells. Int J Cancer 52:778-784.
16. Hansen MB, Nielsen SE, Berg K. 1989. Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill. J Immunol Methods 119:203-210.
17. Heisler LE. 1997. Androgen-dependent cell cycle arrest and apoptotic death in PC-3 prostatic cell cultures expressing a full-length human androgen receptor. Mol Cell Endocrinol 126:2172.
18. Hobisch A, Culig Z, Radmayr C, Bartsch G, Klocker H, Hittmair A. 1995. Distant metastases from prostatic carcinoma express androgen receptor protein. Cancer Res 55:3068-3072.
19. Huang Y, Scher BM, Waxman S. 1995. Enhanced apoptosis in leukemia cells following treatment with combination fluoropyrimidines and differentiation inducers. Mol Cell Diff 3:241-260.
20. Isaacs JT, Coffey DS. 1981. Adaption versus selection as the mechanism responsible for the relapse of prostatic cancer to androgen ablation therapy as studied in the dunning R-3327-H adenocarcinoma. Cancer Res 41:5070-5074.
21. Jutley JK, Reaney S, Kelleher J, Whelan P. 1990. Interactions of retinoic acid and androgens in human prostatic tissue. Prostate 16:299-304.
22. Kokontis J, Takakura K, Hay N, Liao S. 1994. Increased androgen receptor activity and altered c-myc expression in prostate cancer cells after long-term androgen deprivation. Cancer Res 54:1566-1573.
23. Kyprianou N, English HF, Isaacs JT. 1990. Programmed cell death during regression of PC-82 human prostate cancer following androgen ablation. Cancer Res 50:3748-3753.
24. Langeler EG, Van Uffelen CJC, Blankenstein MA, Van Steenbrugge GJ, Mulder E. 1993. Effect of culture conditions on androgen sensitivity of the human prostatic cancer cell line LNCaP. Prostate 23:213-223.
25. Lasnitzki I, Goodman DS. 1974. Inhibition of the effects of methylcholanthrene on mouse prostate in organ culture by vitamin A and its analogs. Cancer Res 34:1564-1571.
26. Lu S, Tsai S, Tsai MJ. 1997. Regulation of androgen-dependent prostate cancer cell growth: androgen regulation of CDK2, CDK4, and CKIp16 genes. Cancer Res 57:4511-4516.
27. Manni A, Santen RJ, Boucher AE, Lipton A, Harvey H, Simmonds M, White-Hershey D, Gordon RA, Rohner TJ, Drago J, Wettlaufer J, Glode LM. 1986. Androgen priming and response to chemotherapy in advanced prostatic cancer. J Urol 136:1242-1246.
28. McDonnell TJ, Troncoso P, Brisbay SM, Logothetis C, Chung LWK, Hsieh J-T, Tu S-M, Campbell ML. 1992. Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 52:6940-6944.
29. Nagle RB, Ahmann FR, McDaniel KM, Paquin ML, Clark VA, Celniker A. 1987. Cytokeratin characterization of human prostatic carcinoma and its derived cell lines. Cancer Res 47:281-286.
30. Newmark JR, Hardy DO, Tonb DC, Carter BS, Epstein JI, Isaacs WB, Brown TR, Barrack ER. 1992. Androgen receptor gene mutation in human prostate cancer. Proc Natl Acad Sci USA 89:6319-6323.
31. Peehl DM, Wong ST, Stamey TA. 1993. Vitamin A regualtes proliferation and differentiation of human prostatic epithelial cells. Prostate 23:69-78.
32. Raffo AJ, Perlman H, Chen M-W, Day ML, Streitman JS, Buttyan R. 1995. Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo. Cancer Res 55:4438-4445.
33. Reichman ME, Hayes RB, Ziegler RG, Schatzkin A, Taylor PR, Kahle LL, Fraumeni Jr. JF. 1990. Serum vitamin A and subsequent development of prostate cancer in the first national health and nutrition examination survey epidemiologic follow-up study. Cancer Res 50:2311-2315.
34. Strohmeyer TG, Slamon DJ. 1994. Proto-oncogenes and tumor suppressor genes in human urological malignancies. J Urol 151:1479-1497.
35. Taplin M-E, Bubley GJ, Shuster TD, Frantz ME, Spooner AE, Ogata GK, Keer HN, Balk SP. 1995. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N Engl J Med 332:1393-1398.
36. Taylor CD, Elson P, Trump DL. 1993. Importance of continued testicular suppression in hormone-refractory prostate cancer. J Clin Oncol 11:2167-2172.
37. Tu SM, McConnell K, Marin MC, Campbell ML, Fernandez A, von-Eschenbach AC, McDonnell TJ. 1995. Combination adriamycin and suramin induces apoptosis in bcl-2 expressing prostate carcinoma cells. Cancer Lett 93:147-155.
38. Updhyay S, Li G, Liu H, Chen YQ, Sarkar FH, Kim HC. 1995. bcl-2 suppresses expression of p21 WAF/CIP1 in breast epithelial cells. Cancer Res 55:4520-4524.
39. Veldscholte J, Ris-Stalpers C, Kuiper GGJM, Jenster G, Berrevoets C, Claassen E, Van Rooij HCJ, Trapman J, Brinkmann AO, Mulder E. 1990. A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochem Biophys Res Commun 173:534-540.
40. Visakorpi T, Hyytinen E, Koivisto P, Tanner M, Keinänen R, Palmberg C, Palotie A, Tammela T, Isola J, Kallioniemi O-P. 1995. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nature Genetics 9:401-406.
41. Weinberg R. 1995. The retinoblastoma protein and the cell cycle. Cell 81:323-330.
42. Wright GLJ, Grob BM, Haley C, Grossman K, Newhall K, Petrylak D, Troyer J, Konchuba A, Schellhammer PF, Moriarty R. 1996. Up-regulation of prostate-specific membrane antigen after androgen-deprivation therapy. Urology 48:326-334.
43. Zhau HYE, Chang S-M, Chen B-Q, Wang Y, Zhang H, Kao C, Sang QA, Pathak SJ, Chung LWK. 1996. Androgen-repressed phenotype in human prostate cancer. Proc Natl Acad Sci USA 93:15152-15157.